https://www.selleckchem.com/pr....oducts/pilaralisib-x
99, p = 4.68E-04). Leave-one-out experiments demonstrated significant concordance between observed and DDPP-predicted PFS (r = 0.9, p = 0.015) for patients treated with everolimus. Notwithstanding the small cohort and pending further prospective validation, the prototype of DDPP offers the potential to transform patients' treatment selection with a tumor- and treatment-agnostic predictor of outcomes (duration of PFS). Systematic review and network meta-analysis. Intermittent catheterization (IC) is considered the standard trea